KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EBT: 2013-2024

Historic EBT for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.

  • Palvella Therapeutics' EBT fell 128.55% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 74.03%. This contributed to the annual value of -$17.4 million for FY2024, which is 193.27% down from last year.
  • As of Q4 2024, Palvella Therapeutics' EBT stood at -$4.0 million, which was up 41.68% from -$6.8 million recorded in Q3 2024.
  • Palvella Therapeutics' EBT's 5-year high stood at $13.8 million during Q4 2023, with a 5-year trough of -$19.0 million in Q3 2021.
  • Over the past 3 years, Palvella Therapeutics' median EBT value was -$7.1 million (recorded in 2022), while the average stood at -$5.9 million.
  • Per our database at Business Quant, Palvella Therapeutics' EBT crashed by 1,508.69% in 2020 and then surged by 223.93% in 2023.
  • Over the past 5 years, Palvella Therapeutics' EBT (Quarterly) stood at -$12.4 million in 2020, then climbed by 11.27% to -$11.0 million in 2021, then fell by 1.48% to -$11.2 million in 2022, then spiked by 223.93% to $13.8 million in 2023, then slumped by 128.55% to -$4.0 million in 2024.
  • Its EBT stands at -$4.0 million for Q4 2024, versus -$6.8 million for Q3 2024 and -$4.2 million for Q2 2024.